Skip to main content
Clinical Trials/NCT05554016
NCT05554016
Recruiting
Not Applicable

The UFO (Ultra Processed Foods in Obesity) Project

Federico II University1 site in 1 country200 target enrollmentSeptember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity, Morbid
Sponsor
Federico II University
Enrollment
200
Locations
1
Primary Endpoint
Dietary UPF intake
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

The childhood obesity prevalence has increased dramatically in the last decades, affecting more than 340 million children worldwide. This condition is the major risk factor for a set of metabolic abnormalities, also known as metabolic syndrome, a condition that reduce life expectancy by 5-20 years. Changes in the global food system, and the increased consumption of ultra-processed foods (UPFs), may have contributed to the increase in the prevalence of childhood obesity and related morbidities. The mechanisms by which UPFs might promote obesity and metabolic syndrome could be multiple and not completely identified.

The Ultra-processed Food in Obesity (UFO) Project has been designed to investigate the potential associations between UPFs intake and MetS in pediatric subjects

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
February 1, 2026
Last Updated
11 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federico II University
Responsible Party
Principal Investigator
Principal Investigator

Roberto Berni Canani, MD, PhD

Professor of Pediatrics

Federico II University

Eligibility Criteria

Inclusion Criteria

  • Caucasian ethnicity, both sexes, age ≥6 and ≤18 years, diagnosis of obesity (Group 1), diagnosis of obesity and Metabolic Syndrome (Group 2), and age- and sex-matched healthy controls (Group 3).

Exclusion Criteria

  • Non-Caucasian ethnicity;
  • Age \<6 or \>18 years;
  • Concomitant presence of chronic diseases, neoplasms, immunodeficiencies, chronic infections,autoimmune diseases, chronic inflammatory bowel disease, celiac disease, metabolic-genetic diseases, cystic fibrosis and other chronic lung diseases, cardiovascular/respiratory/gastrointestinal malformations, neuropsychiatric disorders, and neurological disorders;
  • Intake of antibiotics and/or pre/pro/synbiotics;
  • History of obesity surgery and onset of diarrhea or acute gastrointestinal illness during the 12 weeks prior to enrollment;
  • Presence of tattoos, scars, moles or special lesions on both forearms.

Outcomes

Primary Outcomes

Dietary UPF intake

Time Frame: At enrollment

The assessment of dietary UPF intake will be carried out through a 7-day food diary.

Secondary Outcomes

  • Skin AGEs levels(At enrollment)
  • MicroRNA-221 expression(At enrollment)
  • Daily dietary intake of AGEs(At enrollment)
  • Mitochondrial metabolism(At enrollment)
  • Ghrelin(At enrollment)
  • Leptin(At enrollment)
  • Soluble form of RAGE expression(At enrollment)
  • Oxidative stress(At enrollment)
  • Interleukin-6(At enrollment)
  • Daily intake of energy and nutrients(At enrollment)
  • RAGE expression in peripheral blood mononuclear cells(At enrollment)

Study Sites (1)

Loading locations...

Similar Trials